Supercharged immune cells take on Hard-to-Treat lymphoma

NCT ID NCT04664179

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 09, 2026 · Updated 21 times

Summary

This study tests a new treatment for people with EBV-positive Hodgkin or non-Hodgkin lymphoma that has returned or not gone away. The treatment uses the patient's own T-cells that are genetically modified to produce a protein called C7R, which helps them survive longer in the body. The goal is to find the safest dose and see if these longer-lasting T-cells can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV-RELATED LYMPHOPROLIFERATIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Houston Methodist Hospital
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Texas Children's Hospital
NOT_YET_RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.